theguardian.com
🌐 85% Global Worthiness
NHS Approves New Drug for Uveal Melanoma, Boosting Survival Rates
The NHS will offer tebentafusp, a new drug for uveal melanoma, to hundreds of patients in England, increasing three-year survival rates by 9% compared to current treatments, offering a significant improvement for this rare and difficult-to-treat cancer.
NHS Approves New Drug for Uveal Melanoma, Boosting Survival Rates
The NHS will offer tebentafusp, a new drug for uveal melanoma, to hundreds of patients in England, increasing three-year survival rates by 9% compared to current treatments, offering a significant improvement for this rare and difficult-to-treat cancer.
Progress
40% Bias Score
Good Health and Well-being